Arcturus Therapeutics Holdings Inc. (ARCT)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$213.4M
Cash & Equivalents
$19.4M
Quarterly Burn Rate
33 mo
Est. Cash Runway
$218M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06488313 A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD PHASE2 Recruiting 9

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ARCT.

SEC EDGAR Filings

All SEC filings for Arcturus Therapeutics Holdings Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.